Cambridge Trust’s ARK Genomic Revolution ETF ARKG Stock Holding History

Cambridge Trust’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-72	Closed	-$2K	–	799
2022 Q3	$2K	Hold	72	–	–	﹤0.01%	769
2022 Q2	$2K	Hold	72	–	–	﹤0.01%	801
2022 Q1	$3K	Hold	72	–	–	﹤0.01%	845
2021 Q4	$4K	Buy	+72	New	+$4.98K	﹤0.01%	902

Other funds holding ARKG

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Cambridge Trust's ARKG Position: Q4 2022 in Review

Cambridge Trust sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2022, closing a stake of 72 shares — an estimated $2K sold.

Cambridge Trust first reported a position in ARKG in Q4 2021 and held it in 4 quarters. The position peaked at $4K in Q4 2021. 319 funds tracked by Wall St. Rank hold ARKG as of Q4 2022.

Cambridge Trust reported no remaining ARK Genomic Revolution ETF position as of Q4 2022 after selling out during the quarter.
Cambridge Trust sold 72 ARK Genomic Revolution ETF shares in Q4 2022, an estimated $2K.
Cambridge Trust first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 4 quarters.
Cambridge Trust's ARK Genomic Revolution ETF position peaked at $4K in Q4 2021.
319 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2022.

Based on Cambridge Trust's 13F filing for Q4 2022, filed 10 Jan 2023.